17 March 2017
In this report we highlight some of the major recent developments, important catalysts and current trends occurring in the arthritis drug development field.
Included in this report:
Investigative News
- Humira biosimilars unlikely to launch before Amgen’s Amjevita or by 2018 - legal experts
- Lilly’s Baricitinib uptake faces barrier despite superior RA data, pricing below Xeljanz, Humira the smarter strategy – experts
- Regeneron/Sanofi’s sarilumab not expected to steal significant RA market from Roche’s Actemra – experts
- Regeneron/Sanofi’s sarilumab unlikely to nab front-line status from anti-TNFs despite promise – experts
- Axsome’s AXS-02 oral option unimpressive over IV for osteoarthritis with bone marrow lesions – experts
- Axsome’s oral drug for osteoarthritis with BML has experts lukewarm on Phase III with scant data
- Cara’s CR845 pain data in osteoarthritis triggers Phase IIb expert optimism for 5mg dose, long-term safety questions
- Cara’s CR845 for OA pain has enough market demand despite lukewarm efficacy expectations – experts
- Eli Lilly’s Taltz likely to match Novartis’ Cosentyx in psoriatic arthritis treatment paradigm, slight edge debated – experts
- And more
Data Analysis
- Graph 1: Pharma and Biotech Sponsored Trial Initiations Involving a Drug or Biologic from 2012-2016
- Graph 2: Number of Drugs Currently in Clinical Development
- Graph 3: Global Estimated Sales for Select JAK Inhibitors from 2017-2023
- Graph 4: Global Estimated Sales for Key Approved TNF Inhibitors from 2017-2021
- Graph 5: Estimated Sales for Select Anti-IL-6 Agents from 2017-2021
- Graph 6: Global Estimated Arthritis-Specific Cosentyx Sales from 2017-2021
- Graph 7: Global Estimated Psoriatic Arthritis-Specific Taltz Sales 2018-2020
- And more